Degarelix Side Effects: Safety Signals and Warnings
Degarelix safety concerns are compound-specific. The main listed side effects are Injection site reactions (pain, erythema, swelling), Hot flashes, and Weight gain. The main warning signals are Injection site reactions occur in ~40% of patients, QT prolongation possible - monitor ECG in at-risk patients, and Hyperglycemia and diabetes risk with long-term androgen deprivation.
Direct Answer
Degarelix (Firmagon) is FDA-approved for advanced prostate cancer with Phase 3 data demonstrating faster testosterone suppression to castrate levels than LHRH agonists (within 3 days vs. 3-4 weeks), without the initial testosterone flare. Multiple comparative trials establish it as a first-line option in patients requiring rapid androgen deprivation. A highly validated prostate cancer treatment with clear pharmacological advantages over GnRH agonists in specific clinical scenarios.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Sexual Health
- Best for
- Advanced prostate cancer androgen deprivation, rapid testosterone suppression, GnRH antagonist pharmacology
Reported Side Effects
- Injection site reactions (pain, erythema, swelling)
- Hot flashes
- Weight gain
- Fatigue
- Increased liver enzymes
Warnings
- Injection site reactions occur in ~40% of patients
- QT prolongation possible - monitor ECG in at-risk patients
- Hyperglycemia and diabetes risk with long-term androgen deprivation
- Bone density loss with prolonged therapy
Known or Plausible Interactions
- QT-prolonging medications (additive QT risk)
- Drugs affecting hepatic metabolism
- Anticoagulants (injection site hematoma risk)
Regulatory Context
FDA-approved for the treatment of advanced prostate cancer. Available by prescription only. Marketed as Firmagon by Ferring Pharmaceuticals.
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | Testosterone Suppression (Level A), Prostate Cancer Control (Level A), and Cardiovascular Events (Level B) |
| Primary citation count | 3 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Degarelix Side Effects: Safety Signals and Warnings." Last reviewed 2026-04-04. https://examinepeptides.com/answers/degarelix-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.